KR20230172508A - 안정성이 개선된 항-tslp fab - Google Patents

안정성이 개선된 항-tslp fab Download PDF

Info

Publication number
KR20230172508A
KR20230172508A KR1020237038201A KR20237038201A KR20230172508A KR 20230172508 A KR20230172508 A KR 20230172508A KR 1020237038201 A KR1020237038201 A KR 1020237038201A KR 20237038201 A KR20237038201 A KR 20237038201A KR 20230172508 A KR20230172508 A KR 20230172508A
Authority
KR
South Korea
Prior art keywords
fab
tslp
cells
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237038201A
Other languages
English (en)
Korean (ko)
Inventor
롤란드 빌헬름 콜베크
엠마 수잔느 코헨
캐서린 유지니 헌팅턴
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20230172508A publication Critical patent/KR20230172508A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237038201A 2021-04-19 2022-04-19 안정성이 개선된 항-tslp fab Pending KR20230172508A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
EP21169183.7 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (1)

Publication Number Publication Date
KR20230172508A true KR20230172508A (ko) 2023-12-22

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038201A Pending KR20230172508A (ko) 2021-04-19 2022-04-19 안정성이 개선된 항-tslp fab

Country Status (19)

Country Link
US (1) US20240199730A1 (https=)
EP (1) EP4326767A1 (https=)
JP (1) JP2024516962A (https=)
KR (1) KR20230172508A (https=)
CN (1) CN117222665A (https=)
AR (1) AR125379A1 (https=)
AU (1) AU2022263281A1 (https=)
BR (1) BR112023021587A2 (https=)
CA (1) CA3216894A1 (https=)
CL (1) CL2023003082A1 (https=)
CO (1) CO2023015286A2 (https=)
CR (1) CR20230533A (https=)
EC (1) ECSP23086870A (https=)
IL (1) IL307651A (https=)
MX (1) MX2023012266A (https=)
PH (1) PH12023552762A1 (https=)
SA (1) SA523451188B1 (https=)
TW (1) TW202306982A (https=)
WO (1) WO2022223514A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202529811A (zh) 2024-01-29 2025-08-01 瑞典商阿斯特捷利康公司 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2024516962A (ja) 2024-04-18
MX2023012266A (es) 2023-10-24
TW202306982A (zh) 2023-02-16
CL2023003082A1 (es) 2024-04-19
EP4326767A1 (en) 2024-02-28
CN117222665A (zh) 2023-12-12
CO2023015286A2 (es) 2024-02-05
BR112023021587A2 (pt) 2023-12-19
SA523451188B1 (ar) 2025-06-22
AR125379A1 (es) 2023-07-12
CA3216894A1 (en) 2022-10-27
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
IL307651A (en) 2023-12-01
PH12023552762A1 (en) 2024-04-15
AU2022263281A1 (en) 2023-11-09
US20240199730A1 (en) 2024-06-20
ECSP23086870A (es) 2023-12-29
WO2022223514A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US20240199730A1 (en) An anti-tslp fab with improved stability
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
EP4289861A1 (en) Antibodies against human tslp and use thereof
KR101824512B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
US11673950B2 (en) ILT7 binding molecules and methods of using the same
CN113150146B (zh) IL-4Rα抗体及其用途
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
NZ586027A (en) Monoclonal antibodies that bind to human granulocyte macrophage colony stimulating factor and medical compositions comprising same
CN112654640B (zh) 抗IL-1β的抗体、其药物组合物及其用途
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN103974975A (zh) 抗假单胞菌Psl结合分子及其用途
CN114907479B (zh) 抗cd112r抗体及其用途
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
EP3891180B1 (en) Humanised anti-il17br antibody
EA052142B1 (ru) Fab К TSLP С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
JP5476310B2 (ja) ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
RU2825460C1 (ru) Антитела к TSLP человека и их применение
WO2019183639A1 (en) Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
US20230279092A1 (en) Immunocytokines for treatment of autoimmune and inflammatory conditions
CN115340604A (zh) Tim-3全人源单克隆抗体及其应用
HK40034288A (en) Il-2 muteins and uses thereof
BR112018067951B1 (pt) Anticorpo anti- transcrito 7 semelhante à imunoglobulina, composição farmacêutica e uso dos mesmos
NZ624583B2 (en) Antibody molecules having specificity for human ox40
NZ721624B2 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250414

Comment text: Request for Examination of Application